Monitor upcoming quarterly filings for revenue growth from European adoption; the clinical data is encouraging but conference presence alone does not drive near-term revenue.
Price Chart
Executive Summary
IceCure Medical issued a press release highlighting ProSense cryoablation presentations and workshops at the EUSOBI 2026 breast imaging conference. The filing reports 12-month clinical data showing objective response rates of 97.5% (cryoablation plus endocrine therapy) and 91.7% (cryoablation alone), but contains no new revenue, earnings, or regulatory milestones — it is a routine conference update.
Key Facts
- 12-month objective response rate of 97.5% among 40 patients treated with cryoablation plus endocrine therapy
- 12-month objective response rate of 91.7% among 24 patients treated with cryoablation alone
- ProSense featured in two scientific sessions and two workshops at EUSOBI 2026
- Each workshop attracted nearly 70 participants
- No financial data, revenue, earnings, or regulatory updates provided in the filing
Financial Impact
No financial figures reported; filing is a routine conference update with no direct revenue or earnings impact
Risk Factors
- No new regulatory approvals or commercial contracts announced
- Forward-looking statements about adoption are unquantified and non-binding
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-108763 |
| Document: ea030843901ex99-1.htm | 0001213900-26-108763 |
| Document: 0001213900-26-108763-index-headers.html | 0001213900-26-108763 |
| Document: 0001213900-26-108763-index.html | 0001213900-26-108763 |
| Document: 0001213900-26-108763.txt | 0001213900-26-108763 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 14d ago | 6-K | $1.10 | awaiting T+60 | — | $1.03 (−6.36%) |
Oct 5, 2026 22d ago | 6-K | $1.27 | awaiting T+60 | — | $1.03 (−18.90%) |
Oct 5, 2026 22d ago | 6-K | $1.54 | awaiting T+60 | — | $1.03 (+33.12%) |
Sep 10, 2026 6w ago | 6-K | $2.14 | awaiting T+60 | — | $1.03 (−51.87%) |
Aug 24, 2026 9w ago | 6-K | $2.27 | awaiting T+60 | — | $1.03 (−54.63%) |
Aug 19, 2026 9w ago | EFFECT | $2.52 | awaiting T+60 | — | $1.03 (+59.13%) |
Aug 14, 2026 10w ago | 6-K | $2.82 | awaiting T+60 | — | $1.03 (−63.48%) |
Aug 12, 2026 10w ago | 6-K | $3.11 | awaiting T+60 | — | $1.03 (−66.83%) |
Jul 6, 2026 16w ago | EFFECT | $4.61 $1.59 | ▲ +65.51% | ▲ +67.23% | $1.03 (+77.66%) |
Jun 26, 2026 17w ago | 6-K | $5.26 $1.95 | ▲ +62.93% | ▲ +67.31% | $1.03 (+80.42%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers